Table 1.

Indication for TSH suppressive therapy in patients with differentiated thyroid cancer according to the ongoing risk stratification^a.

Thyroid surgery	Total thyroidectomy				Lobectomy
Response	Excellentb	Indeterminatec	Biochemical incompleted	Structural incompletee	Low-risk patients
TSH suppression	No TSH ≥ 0.5 mU/mL	Mild TSH 0.1–0.5 mU/L	Mild TSH 0.1–0.5 mU/L	Moderate 0.1–0.01 mU/L	No TSH ≥ 0.5 mU/mL
Benefit/risk assessment	Consider potential harm of exogenous thyrotoxicosis (atrial fibrillation, osteoporosis, osteopenia, tachycardia, older age, menopause) and eventually downgrade the TSH target values

^aAccording to the latest ATA guidelines (8). ^bExcellent response: no clinical, biochemical, or structural evidence of disease (8). ^cIndeterminate response: nonspecific biochemical or structural findings that cannot be confidently classified as either benign or malignant. This includes patients with stable or declining Tg antibody levels without definitive structural evidence of disease (8). ^dBiochemical incomplete response: abnormal Tg or rising Tg antibody levels in the absence of localizable disease (8). ^eStructural incomplete response: persistent or newly identified loco-regional or distant metastases (8).